Product logins

Find logins to all Clarivate products below.


Gram-Negative Infections: How Will U.S. Payer and Prescriber Receptivity to Novel Antibiotics Shape the Market for These Therapies? | Physician & Payer Forum | US | 2014

Gram-negative infections (GNIs) represent a high-value segment of the antibiotic market and are often treated in the hospital setting. Infections due to Gram-negative pathogens (GNPs) are frequently severe and difficult to treat – particularly those due to multi-drug-resistant (MDR) GNPs, the prevalence of which continues to increase. Despite the availability of broad-spectrum antibiotics from multiple drug classes (e.g., carbapenems, quinolones, cephalosporins, beta-lactam/beta-lactamase inhibitors) to treat hospitalized patients with GNIs, the rising rates of antibiotic resistance and scarce new drug launches have resulted in highly-limited treatment options for an increasing number of GNI patients. However, several late-stage products targeting drug-resistant GNPs are expected to launch near-term, notably expanding the physicians’ armamentarium for these infections. These include two promising cephalosporin/beta-lactamase inhibitor combinations, Cubist’s ceftolozane/tazobactam (formerly CXA-201) and Actavis/AstraZeneca’s ceftazidime/avibactam (CAZ-AVI), as well as Tetraphase’s novel tetracycline derivative, eravacycline. Multi-pronged efforts are currently underway to promote and incentivize the development of novel antibiotics, including those targeting MDR GNPs. The Infectious Disease Society of America’s proposed Limited Population Antibacterial Drug (LPAD) approval mechanism is one such initiative that could expedite clinical development timelines and decrease associated costs for novel antibiotics targeting MDR pathogens.

Related Market Assessment Reports

Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Human Immunodeficiency Virus – Landscape & Forecast – Disease Landscape & Forecast (G7)
The HIV therapy market is undergoing significant transformation, driven by innovative ARVs and evolving treatment strategies. The market is crowded with many approved ARVs, including STRs such as…
Report
Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…
Report
Multiple Myeloma – Geographic Focus: China – Multiple Myeloma – China In-Depth (China)
China’s multiple myeloma therapy market is evolving rapidly, driven by an increasing disease burden and advances in treatment options. Current therapies in China largely mirror global standards;…